RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium
25 January 2022 - 12:00AM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company that is developing and commercializing a
technology platform that enables point-of-care autologous skin
restoration for multiple unmet needs, announced today that six
abstracts highlighting the clinical benefits of the RECELL®
Autologous Cell Harvesting Device (RECELL® System) have been
accepted at the 44th Annual John A. Boswick Burn & Wound Care
Symposium. The international conference will be held in Maui,
Hawaii, January 22-27, and covers the latest advancements in burn
care, wound healing, and infection control.
“The physician-initiated research being presented at this year’s
Boswick Symposium underscores how the RECELL® System is advancing
treatment of burn wounds, both as a monotherapy and in combination
with complementary technologies,” said Dr. Mike Perry, Chief
Executive Officer of AVITA Medical. “With completion
of enrollment in both our vitiligo and
soft tissue reconstruction pivotal clinical trials,
we look forward to progressing our pipeline and simultaneously
beginning to realize the immense potential of this innovative
technology platform benefitting a broad array of patients with skin
defects or wounds.”
RECELL® System Abstracts
- Autologous keratinocyte suspension
in conjunction with fibrin sealant for the treatment of partial
thickness burns. Author: E. Brown, Texas Tech University HSC School
of Medicine, Lubbock, TX
- Utilizing glabrous skin from the
palm to source autologous regenerative epidermal suspension for
deep partial thickness palmar burns. Author: P. Fidler, Burn and
Reconstructive Centers of America
- A Retrospective Review of Clinical
Outcomes in Superficial and Deep Second-Degree Burn Patients
treated with Autologous Skin Cell Suspension (RECELL) and Split
Thickness Skin Graft. Author: K. Henry, Jacobi Medical
Center, Bronx, New York
- Simplifying the Treatment Algorithm
by Reducing Number of Autografting Procedures: Use of ASCS for
Thermal Burn Injuries. Author: W. Hickerson, AVITA Medical
Consultant
- The holy grail? Experience with
autologous skin cell suspension combined with a poly-lactic acid
dressing. Author: A. Khandelwal, MD, FACS, FICS, Akron Children’s
Hospital, Akron, OH
- Biodegradable Temporizing Matrix and
Autologous Skin Cell Suspension in Necrotizing Soft Tissue
Infection: A Case Report. Author: A. Raghuram, Texas Tech
University HSC School of Medicine, Lubbock, TX
For more information about the RECELL System, please visit
www.avitamedical.com.
ABOUT AVITA MEDICAL, INC.AVITA Medical is a
regenerative medicine company with a technology platform positioned
to address unmet medical needs in burns, chronic wounds, and
aesthetics indications. AVITA Medical’s patented and proprietary
collection and application technology provides innovative treatment
solutions derived from the regenerative properties of a patient’s
own skin. The medical devices work by preparing a RES® REGENERATIVE
EPIDERMAL SUSPENSION, an autologous suspension comprised of the
patient’s skin cells necessary to regenerate natural healthy
epidermis. This autologous suspension is then sprayed onto the
areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was
approved by the U.S. Food and Drug Administration (FDA) in
September 2018. The RECELL System is indicated for use in the
treatment of acute thermal burns. The RECELL System is used to
prepare Spray-On Skin™ Cells using a small amount of a patient’s
own skin, providing a new way to treat severe burns, while
significantly reducing the amount of donor skin required. The
RECELL System is designed to be used at the point of care alone or
in combination with autografts depending on the depth of the burn
injury. Compelling data from randomized, controlled clinical trials
conducted at major U.S. burn centers and real-world use in more
than 10,000 patients globally reinforce that the RECELL System is a
significant advancement over the current standard of care for burn
patients and offers benefits in clinical outcomes and cost savings.
Healthcare professionals should read the INSTRUCTIONS FOR USE -
RECELL® Autologous Cell Harvesting Device
(https://recellsystem.com/) for a full description of indications
for use and important safety information including
contraindications, warnings, and precautions.
In international markets, our products are marketed under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, chronic wounds, and aesthetics. The
RECELL System is TGA-registered in Australia and received CE-mark
approval in Europe. To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTSThis press release includes forward-looking
statements. These forward-looking statements generally can be
identified by the use of words such as “anticipate,” “expect,”
“intend,” “could,” “may,” “will,” “believe,” “estimate,” “look
forward,” “forecast,” “goal,” “target,” “project,” “continue,”
“outlook,” “guidance,” “future,” other words of similar meaning and
the use of future dates. Forward-looking statements in this press
release include, but are not limited to, statements concerning,
among other things, our ongoing clinical trials and product
development activities, regulatory approval of our products, the
potential for future growth in our business, and our ability to
achieve our key strategic, operational and financial goal.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Each forward-looking
statement contained in this press release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others, the timing of regulatory
approvals of our products; physician acceptance, endorsement, and
use of our products; failure to achieve the anticipated benefits
from approval of our products; the effect of regulatory actions;
product liability claims; risks associated with international
operations and expansion; and other business effects, including the
effects of industry, economic or political conditions outside of
the company’s control. Investors should not place considerable
reliance on the forward-looking statements contained in this press
release. Investors are encouraged to read our publicly available
filings for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this release, and we undertake no
obligation to update or revise any of these statements.
This press release was authorized by the review committee of
AVITA Medical, Inc.
FOR FURTHER INFORMATION:
U.S. MediaSam Brown, Inc.Christy CurranPhone
+1-615-414-8668christycurran@sambrown.comO.U.S.
MediaRudi Michelson Phone +61 (0)3 9620 3333 Mobile +61
(0)411 402 737 rudim@monsoon.com.au |
InvestorsICR WestwickeCaroline CornerPhone
+1-415-202-5678 caroline.corner@westwicke.com |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024